18:00 , Oct 25, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Tuberculosis Patient sample and mouse studies suggest inhibiting miR-27a could help treat tuberculosis (TB). In peripheral blood mononuclear cells (PBMCs) from patients with active pulmonary TB, levels of miR-27a were higher than in PBMCs...
18:04 , Aug 29, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma; liver cancer; pancreatic cancer; colorectal cancer Mouse studies suggest inhibiting CD144 degradation could help treat melanoma, liver, pancreatic and colorectal cancers. In mouse models of melanoma and hepatocellular carcinoma (HCC), a previously reported...
07:00 , Oct 17, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Ischemia/reperfusion injury MicroRNA-27a (miR-27a); VE-cadherin (CD144; cadherin-5) Mouse studies suggesting blocking the interaction between miR-27a and VE-cadherin transcripts could help...